THE Antibodies and Experimental Biomodels Laboratory (LABEX) is to produce broad spectrum tumor markers for wide-ranging use within the national public health system and for export, principally used in the context of cancer diagnosis. Dr. Agustín Lage, director of the Molecular Immunology Center (CIM), to which the center is attached, stated that this product reflects the positive results of 20 years as an entity focused on research, production and marketing.
The scientist explained that the laboratory, which emerged from the capital’s Medical University, has made significant advances in the manufacture of monoclonal antibodies for blood banks, classification of the Rh factor and the characterization of lymphocytes, in addition to other lines of vital importance to health services.
He noted that LABEX began exporting to Brazil in 2012 and is developing negotiations with other countries, as part of the commercial group BioCubaFarma, responsible for transactions related to national biotechnological products and pharmaceuticals.
Lage commented that the CIM collective supplies the Pedro Kouri Institute of Tropical Medicine with all reagents for treating patients with HIV/AIDS and plays an important part in ensuring diagnostic medications for Cuban medical services.
He said that according to modern oncology regulations, tumor markers function as labels to identify malignant formations, based on molecular characteristics, and thus support the efficacy of treatment.
Inaugurated in July 1993 by the leader of the Cuban Revolution, Fidel Castro, LABEX has benefited four million-plus Cubans and international patients, to date, and its contributions to immunology, microbiology, hematology, endocrinology and pathological anatomy labs are decisive. (PL)
Leave a comment
No comments yet.